Charles River Laboratories International, Inc. $CRL Shares Bought by LSV Asset Management

LSV Asset Management grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,773.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 297,800 shares of the medical research company’s stock after purchasing an additional 281,900 shares during the period. LSV Asset Management owned approximately 0.61% of Charles River Laboratories International worth $46,594,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Caprock Group LLC acquired a new position in Charles River Laboratories International in the third quarter valued at about $1,856,000. Rhumbline Advisers raised its stake in shares of Charles River Laboratories International by 1.5% in the 3rd quarter. Rhumbline Advisers now owns 96,569 shares of the medical research company’s stock valued at $15,109,000 after acquiring an additional 1,427 shares during the period. Madison Asset Management LLC acquired a new position in shares of Charles River Laboratories International in the 3rd quarter worth approximately $1,935,000. Versor Investments LP purchased a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $921,000. Finally, Midwest Trust Co increased its holdings in Charles River Laboratories International by 3.5% in the 3rd quarter. Midwest Trust Co now owns 27,047 shares of the medical research company’s stock valued at $4,232,000 after purchasing an additional 906 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $161.15 on Friday. The business has a 50-day simple moving average of $203.27 and a 200-day simple moving average of $179.67. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88. The company has a market cap of $7.93 billion, a PE ratio of -103.30, a P/E/G ratio of 4.76 and a beta of 1.63.

Analysts Set New Price Targets

CRL has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Citigroup increased their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Argus set a $200.00 target price on Charles River Laboratories International in a research report on Monday, November 17th. Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Finally, Barclays raised their price objective on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $209.46.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.